Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

This study has been terminated.
(Drug Supply Issue)
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Comprehensive Cancer Center of Wake Forest University
ClinicalTrials.gov Identifier:
NCT00573989
First received: December 13, 2007
Last updated: August 30, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)